Effect of Non-nutritive Sweeteners on Vascular Function in Humans (SOSweet)

In recent decades, low-to-null caloric, non-nutritive sweeteners (NNS) have been increasingly used, replacing and offering an alternative to food and beverages sweetened by high-energy, added sugars. Indeed, by providing consumers with products that have a sweet taste with low energy content, NNS appear to be the magic bullet to enhance weight loss and reduce cardio-metabolic diseases. However, a recent meta-analysis of randomized trials does not show any benefit of NNS consumption on body weight loss. Moreover, epidemiological, descriptive and experimental studies have recently reported that NNS consumption is paradoxically associated with weight gain, glucose intolerance and increased risk of type 2 diabetes and/or cardiovascular events. Among the approved NNS, sucralose and AceK, both high intensity (respectively ~500-600 and 200 times sweeter than sugar) are the most widely used in foods and drinks, accounting more than 62 % of the global artificial sweetener market. Recent experimental data show an effect of sucralose and AceK (and other NNS) consumption on vascular reactivity in response to a physiological stress (hyperglycemic load) in rats. Since sweet taste receptors (T1R) have been recently found in the endothelium, investigators hypothesize that NNS, and especially sucralose and AceK, a potent T1R agonist, impairs micro- and macrovascular reactivity in humans, which, to the best of our knowledge, has never been explored.

Study Overview

• Status: Recruiting
• Conditions: Non Nutritive Sweeteners Consumption
• Intervention / Treatment: Dietary supplement: Non Nutritive Sweeteners

Detailed Description

In recent decades, low-to-null caloric, non-nutritive sweeteners (NNS) have been increasingly used, replacing and offering an alternative to food and beverages sweetened by high-energy, added sugars. Indeed, by providing consumers with products that have a sweet taste with low energy content, NNS appear to be the magic bullet to enhance weight loss and reduce cardio-metabolic diseases. However, a recent meta-analysis of randomized trials does not show any benefit of NNS consumption on body weight loss. Moreover, epidemiological, descriptive and experimental studies have recently reported that NNS consumption is paradoxically associated with weight gain, glucose intolerance and increased risk of type 2 diabetes and/or cardiovascular events. Among the approved NNS, sucralose and AceK, both high intensity (respectively ~500-600 and 200 times sweeter than sugar) are the most widely used in foods and drinks, accounting more than 62 % of the global artificial sweetener market. Recent experimental data show an effect of sucralose and AceK (and other NNS) consumption on vascular reactivity in response to a physiological stress (hyperglycemic load) in rats. Since sweet taste receptors T1R have been recently found in the endothelium, investigators hypothesize that NNS, and especially sucralose and AceK, a potent T1R agonist, impairs micro- and macrovascular reactivity in humans, which, to the best of our knowledge, has never been explored.

This is a prospective, single-center, controlled, randomized, double-blind, three-period crossover study

The principal objective is to evaluate the effect of a NNS daily consumption (sucralose or AceK) during 4 weeks on macrovascular endothelial function, in lean and obese subjects compared to placebo.

The principal outcome / endpoint will be based on flow-mediated dilation (FMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected for shear rate, according to current recommendations, after 4 week of NNS (sucralose or AceK) daily consumption compared to placebo

CONDUCT OF THE RESEARCH : Patients will be screened and, if eligible, proposed a 3-period crossover trial (sucralose, AceK, placebo). The order will be randomized. These 3 periods will be separated with wash out periods between one and two weeks. The 3 periods of 4 weeks will be with one visit at the beginning and at the end of each period, i.e. a total of 6 visits. During each beginning and end of period visit, microvascular and macrovascular reactivity tests will be conducted. At the first visit only, microdialysis will be performed.

Number of subjects : 40 Length of the inclusion period: 24 months Length of treatment: 3 one-month periods, and maximum 4 weeks of wash-outs Length of participation for each subject: 4 months Total length of the study (with statistical analysis): 36 months

STATISTICAL ANALYSIS ; The analysis of the primary outcome will be carried on using an analysis of covariance (ANCOVA), adjusted on baseline FMD, with a risk alpha of 0.05 and a power of 80%, two-sided. Investogators estimated within-subject correlation to be close to 0.7, as shown in previous results by our group.5 In order to maximise power, for secondary objectives, the effects of sucralose, AceK, sex, and obesity, will be assessed using mixed-effects models, with the subject as a random factor.

EXPECTED IMPACT : This is a hot topic since recent studies in animals and humans do not support the claims previously submitted to regulatory agencies that NNS, including sucralose and AceK, are stable compounds that are not metabolized in vivo; and have no effect on metabolism. Questioning the physiological inactivity of these extensively used molecules is mandatory since there is a rise in the consumption of NNS-containing products. Moreover, very recent studies are observing an increase in the consumption of diet products, especially in vulnerable groups (obese, diabetic patients, children or pregnant women). New data on the effect of chronic NNS consumption will help revisit the regulatory status of NNS and bring extensive knowledge on the role of T1R receptors on vascular function, which has been hardly ever studied so far. Finally and importantly, vascular function is largely recognized as a strong precursor of cardiovascular disease.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Matthieu ROUSTIT, Pr; Phone Number: 04 76 76 92 60; Email: MRoustit@chu-grenoble.fr
• Study Contact Backup: Name: alicia Guigui, Dr; Phone Number: 04 76 76 92 60; Email: aguigui@chu-grenoble.fr

Study Locations

• France
  • Grenoble, France
    • Recruiting
    • Grenoble University Hospital
    • Contact: Guigui alicia; Email: aguigui@chu-grenoble.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female aged≥ 18 years
• Signed informed consent

• Body mass index:

  • 25 kg/m² ≥ BMI ≥ 18,5 kg/m² (lean subjects)
  • >30 kg/m2, with waist-to-hip ratio >0.9 (subjects with obesity)
• Person who is affiliated to a social security scheme or who is a beneficiary of such a scheme

Exclusion Criteria:

• Any chronic disease with vascular impact (including type 2 diabetes)
• Active tobacco use (any quantity)
• Participant involved in another interventional clinical study
• History of hypersensitivity reaction to products used
• The persons mentioned in articles L1121-5 to L1121-9 of the public health code may not be included in this research (Pregnancy or Lactation ; Females with childbearing potential, defined as a premenopausal female and not using an effective form of birth control. (Effective birth control methods include: oral, implant or patch hormone contraception; intrauterine device; abstinence and outercourse; tubal ligation; vasectomy.) ; Person deprived of liberty by judicial order ; Person under guardianship or curatorship ; Minors ; Adults who are incapable or unable to give their consent ; Cross-over situations)
• Subject who would receive more than 4500 euros in compensation due to his or her participation in other research involving the human person in the 12 months preceding this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: subject with obesity; composed of subject with obesity (Body mass index > 30)	Dietary supplement: Non Nutritive Sweeteners; The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo. The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period.
Experimental: lean subject; composed of healthy volunteers (Body mass index < 30)	Dietary supplement: Non Nutritive Sweeteners; The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo. The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Macrovascular endothelial function	Flow-mediated dilation (FMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected for shear rate, according to current recommendations,6 after 4 week of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Macrovascular non-endothelial function	Nitrate-mediated dilation (NMD), expressed as a percent change from baseline diameter, and corrected on the shear rate, in accordance with guidelines, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Macrovascular endothelial function	Flow-mediated dilation (FMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected on the shear rate, in accordance with guidelines, in response to a glycemic stress, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Macrovascular non endothelial function	Nitrate-mediated dilation (NMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected on the shear rate, in accordance with guidelines, in response to a glycemic stress, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial function	Microvascular reactivity to iontophoresis of acetylcholine (ACh), measured with laser speckle contrast imaging (LSCI), after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular non endothelial function	Microvascular reactivity to iontophoresis of sodium nitroprussiate (SNP), measured with laser speckle contrast imaging (LSCI), after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial and non endothelial function	Microvascular reactivity to local thermal heating, measured with laser speckle contrast imaging (LSCI), after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial function	Microvascular reactivity to iontophoresis of acetylcholine (ACh), measured with laser speckle contrast imaging (LSCI), in response to a glycemic stress, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular non endothelial function	Microvascular reactivity to iontophoresis of sodium nitroprussiate (SNP), measured with laser speckle contrast imaging (LSCI), in response to a glycemic stress, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial and non endothelial function	Microvascular reactivity to local thermal hyperheamia, measured with laser speckle contrast imaging (LSCI), in response to a glycemic stress, after 4 weeks of NNS (sucralose or AceK) daily consumption compared to placebo.	through study completion, an average of 4 months
Macrovascular endothelial function	Flow-mediated dilation (FMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected on the shear rate, in accordance with guidelines 2 hours after an acute intake of NNS (sucralose or AceK) compared to placebo	through study completion, an average of 4 months
Macrovascular non endothelial function	Nitrate-mediated dilation (NMD) of the brachial artery, expressed as a percent change from baseline diameter, and corrected on the shear rate, in accordance with guidelines 2 hours after an acute intake of NNS (sucralose or AceK) compared to placebo	through study completion, an average of 4 months
Microvascular non endothelial function	Microvascular reactivity to iontophoresis of SNP, measured with laser speckle contrast imaging (LSCI), one hour and a half after an acute intake of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial function	Microvascular reactivity to iontophoresis of Ach, measured with laser speckle contrast imaging (LSCI), one hour and a half after an acute intake of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Microvascular endothelial and non endothelial function	Microvascular reactivity to local thermal hyperhemia measured with laser speckle contrast imaging (LSCI) one hour and a half after an acute intake of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of ghrelin, after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of gastric inhibitory peptide (GIP), after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of glucagon like peptide (GLP-1), after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of peptide tyrosine tyrosine (PYY), after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of cholecystokinin (CCK), after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Plasma levels of leptin after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolic function	Glycaemia, after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Metabolomics profiles	Plasma metabolomics profile after 4 weeks daily consumption of NNS (sucralose or AceK) compared to placebo.	through study completion, an average of 4 months
Microvascular and macrovascular endothelial and non endothelial function	Results of FMD, NMD, local thermal hyperaemie (LTH) and iontophoresis of Ach and SNP compared between lean and obese subjects, in response to an acute or daily consumption of NNS (sucralose or AceK) or placebo.	through study completion, an average of 4 months
Microvascular and macrovascular endothelial and non endothelial function	Results of FMD, NMD, LTH, and iontophoresis of Ach and SNP, compared between male and female subjects, in response to an acute or daily consumption of NNS (sucralose or AceK) or placebo.	through study completion, an average of 4 months
Microvascular and macrovascular endothelial and non endothelial function	Results of FMD, NMD, LTH and iontophoresis of Ach and SNP, according to the basal consumption of sweetener, in response to an acute or daily consumption of NNS (sucralose or AceK) or placebo.	through study completion, an average of 4 months
Microdialysis reactivity	Microvascular reactivity by microdialysis of sucralose measured with laser speckle contrast imaging (LSCI)	First visit, one day
Microdialysis reactivity	Microvascular reactivity by microdialysis of AceK measured with laser speckle contrast imaging (LSCI)	First visit, one day
Microdialysis reactivity	Microvascular reactivity by microdialysis of lactisole measured with laser speckle contrast imaging (LSCI)	First visit, one day

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Investigators: Principal Investigator: Matthieu ROUSTIT, Pr, Centre Hospitalier Universitaire Grenoble Alpes

Study record dates

Study Major Dates

• Study Start (Actual): March 28, 2022
• Primary Completion (Estimated): October 1, 2024
• Study Completion (Estimated): November 1, 2024

Study Registration Dates

• First Submitted: September 29, 2021
• First Submitted That Met QC Criteria: October 18, 2021
• First Posted (Actual): October 29, 2021

Study Record Updates

• Last Update Posted (Estimated): December 6, 2023
• Last Update Submitted That Met QC Criteria: December 5, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 38RC19.355

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data can be requested by contacting Prof. Roustit mroustit@chu-grenoble.fr
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No